At a glance · for buyers and watchdogs
AstraZeneca has won £1.1bn across 8 public-sector buyers, with 28 live contracts. No active Companies House risk flags.
Why: top buyer NHS England at 62% · 100% in Medical equipment · 0 active risk flags · 0 modifications.
ESG & policies vault · 0/5
Key governance & sustainability policies. Published documents link out; missing ones are greyed.
Capabilities
What this supplier does, where they sit, who they sell to.
- NHS Framework Agreement, Branded Medicines for London and South of England
- NHS Framework for the North of England, Branded Medicine
- NHS Framework Agreement for Branded medicines - National
Extracted automatically from astrazeneca.co.uk on Jul 2026. Not independently verified — treat as the supplier’s own marketing claims.
Case studies
Delivery stories the supplier has published, with sector and outcome.
No case studies yet
Once a claimed supplier publishes delivery stories — the buyer, the sector, what was delivered and the outcome — they appear here.
Buyer references
Named public-sector contacts who have agreed to act as a reference.
No buyer references yet
Public-sector buyers can confirm they'll act as a reference for this supplier. Confirmed references — with the contract they relate to — show here.
Accreditations & memberships
Independently issued. Verification dates cross-checked against issuer registers.
No accreditations recorded
B-Corp, ISO, Cyber Essentials, Living Wage and similar credentials appear here once added by a claimed supplier and cross-checked against the issuing register.
KPI performance
Delivery, budget and satisfaction scores reported quarterly by buyers.
No verified KPI scores yet
Once buyers report contract KPIs — delivery on time, on budget, satisfaction, adoption and accessibility — a weighted grade and breakdown appear here.
Contracts · 28 live · 22 historic
Pulled from Contracts Finder & Find a Tender. Most recent first.
| Title | Buyer | CPV | Awarded | Value | Term | Status |
|---|---|---|---|---|---|---|
| UK HEALTH AND SECURITY AGENCY | 33651660 | 01 Aug 2026 | £225.4m | 2 yrs | Live | |
| NHS England | — | 01 Jun 2026 | £529.1m | 1.9 yrs | pending | |
| NHS England | 33600000 | 01 Sept 2025 | £9.4m | 2 yrs | Live | |
| NHS England North East and Yorkshire Health and Justice | — | 01 Sept 2025 | £22.1m | 17 mo | pending | |
| NHS England North East and Yorkshire Health and Justice | — | 01 Sept 2025 | £22.1m | 17 mo | pending | |
| NHS England | 33600000 | 01 Sept 2024 | £13.1m | 2 yrs | Live | |
| NHS England | 33600000 | 01 May 2024 | £11.2m | 4 yrs | Live | |
| NHS England | 33600000 | 01 Mar 2024 | £17.6m | 2.5 yrs | Live | |
| NHS England | 33600000 | 01 Sept 2023 | £7.6m | 2 yrs | Closed | |
| NHS England | 33600000 | 01 Sept 2023 | £6.4m | 2 yrs | Closed |
Top buyers · 8 buyers · top 3 = 96%
Share of awarded value. Concentration fires above 40% for any single buyer.
Category mix
CPV-division share of last-12m awarded value. Single-category exposure: 100%.
Geography
Distribution of awarded value by buyer region.
Peers
Suppliers with overlapping CPVs & buyers (last 24m). AstraZeneca highlighted.
| Supplier | SME? | Awarded · 24m | Contracts |
|---|---|---|---|
AS AstraZeneca | No | £754.5m | — |
| Yes | £63.5m | 14 | |
| Yes | £63.1m | 12 | |
| Yes | £63.1m | 8 | |
| Yes | £61.8m | 16 | |
| Yes | £60.5m | 16 |
Red flags · 0 active
Automated scan of Companies House status, charges and insolvency records.
Compliance scorecard
Derived from Companies House filings — not a full supplier-assurance check.
Modifications
Variations to awarded contracts logged under Procurement Act 2023 s.74.
No modifications recorded
No published contract variations for this supplier. Modification notices appear here as they are issued under the Procurement Act 2023.
News mentions
UK trade press & nationals, matched to this supplier.
No news mentions found
We haven't matched any recent UK press coverage to this supplier. Mentions appear here automatically as they're published.
Companies House
Live sync — registered details, directors, PSC and SIC codes.
Registered details
- Company no.
- 03674842
- Status
- Active
- Type
- Private limited
- Incorporated
- 26 Nov 1998
- Reg. office
- 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA
- SIC codes
- 70100
- Last accounts
- 31 Dec 2024
- Next accounts due
- 30 Sept 2026
Directors & PSC
- BOWDEN, Matthew Shaun — secretaryAppointed 01 May 2025
- JERMUTUS, Lutz — directorAppointed 10 Feb 2025
- DE GIORGIO-MILLER, Alexander — directorAppointed 27 Jun 2024
- DOBBER, Rudi — directorAppointed 27 Jun 2024
- GALBRAITH, Susan — directorAppointed 27 Jun 2024
- HARROP, Elaine — directorAppointed 27 Jun 2024
- Astrazeneca Intermediate Holdings Limited — person with significant controlownership of shares 75 to 100 percent · voting rights 75 to 100 percent · right to appoint and remove directors
Financial
Filed accounts from Companies House.
No financial filings on record
Turnover, profit and headcount appear here once audited or micro-entity accounts are filed at Companies House.
Org tree
Group structure and ownership.
Independent. No parent company or subsidiaries recorded at Companies House for this entity.
Social value
Commitments mapped to the Government Social Value Model themes.
No social-value commitments yet
Jobs, skills, environmental, inequality and community commitments appear here once a claimed supplier attributes them to awarded contracts, or once we detect them on the supplier’s website.